title: The impact of national guidelines for the prophylaxis of venous thromboembolism on the complications of arthroplasty of the lower limb.
abstract: The National Institute for Clinical Excellence (NICE) produces recommendations on appropriate treatment within the National Health Service (NHS) in England and Wales. The NICE guidelines on prophylaxis for venous thromboembolism in orthopaedic surgery recommend that all patients be offered a low molecular weight heparin (LMWH). The linked hospital episode statistics of 219 602 patients were examined to determine the rates of complications following lower limb arthroplasty for the 12-month periods prior to and following the publication of these guidelines. These were compared with data from the National Joint Registry (England and Wales) regarding the use of LMWH during the same periods. There was a significant increase in the reported use of LMWH (59.5% to 67.6%, p < 0.001) following the publication of the guidelines. However, the 90-day venous thromboembolism events actually increased slightly following total hip replacement (THR, 1.69% to 1.84%, p = 0.06) and remained unchanged following total knee replacement (TKR, 1.99% to 2.04%). Return to theatre in the first 30 days for infection did not show significant changes. There was an increase in the number of patients diagnosed with thrombocytopenia, which was significant following THR (0.11% to 0.16%, p = 0.04). The recommendations from NICE are based on predicted reductions in venous thromboembolism events, reducing morbidity, mortality and costs to the NHS. The early results in orthopaedic patients do not support these predictions, but do show an increase in complications.
authors.affiliation: Northumbria Healthcare NHS Trust, Northumberland, England. simonjameson@doctors.org.uk
authors.forename: S S
authors.initials: SS
authors.lastname: Jameson
authors.forename: A
authors.initials: A
authors.lastname: Bottle
authors.forename: A
authors.initials: A
authors.lastname: Malviya
authors.forename: S D
authors.initials: SD
authors.lastname: Muller
authors.forename: M R
authors.initials: MR
authors.lastname: Reed
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D001178:Arthroplasty / Q000009:adverse effects*; D004739:England; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D007902:Length of Stay; D035002:Lower Extremity / Q000601:surgery*; D009313:National Health Programs / Q000592:standards; D011183:Postoperative Complications / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D054556:Venous Thromboembolism / Q000517:prevention & control*; D014852:Wales
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight